Skip to main content

Richard Auchus, MD, PhD

Can you share with us how you became interested in CAH and what personal and discipline-related historical features have fueled your interest in advancing therapy for this disease state?

Can you share with us how you became interested in CAH and what personal and discipline-related historical features have fueled your interest in advancing therapy for this disease state?

Richard Auchus, MD, PhD

Once the importance of uncoupling the androstenedione and glucocorticoid axes was understood, what targeting strategies were employed in the CAHtalyst trial that would lead to novel targeting of CRF1 with crinecerfont for CAH?

Once the importance of uncoupling the androstenedione and glucocorticoid axes was understood, what targeting strategies were employed in the CAHtalyst trial that would lead to novel targeting of CRF1 with crinecerfont for CAH?

Richard Auchus, MD, PhD

Can you drill down to the specific parameters—inclusion criteria, glucocorticoid dosing, set points for androstenedione control, overall 2-part trial design—for the pediatric CAHtalyst trial?

Can you drill down to the specific parameters—inclusion criteria, glucocorticoid dosing, set points for androstenedione control, overall 2-part trial design—for the pediatric CAHtalyst trial?

Richard Auchus, MD, PhD

Please discuss the two phases of the CAHtalyst trial in which you compared the placebo group with the crinecerfont arm, and the ability to maintain a down-titrated more physiological glucocorticoid dose.

Please discuss the two phases of the CAHtalyst trial in which you compared the placebo group with the crinecerfont arm, and the ability to maintain a down-titrated more physiological glucocorticoid dose.

Richard Auchus, MD, PhD

Can you go into the specific end points for androstenedione, as well as your criteria for allowing progressive down-titration of glucocorticoid in phase 2 of the CAHtalyst trial?

Can you go into the specific end points for androstenedione, as well as your criteria for allowing progressive down-titration of glucocorticoid in phase 2 of the CAHtalyst trial?

Richard Auchus, MD, PhD

What were you trying to learn in the second phase of CAHtalyst? Whether or not you needed super-physiologic doses of glucocorticoids to reduce/maintain androstenedione in combination with upstream CRF1 inhibition mediated by crinecerfont?

What were you trying to learn in the second phase of CAHtalyst? Whether or not you needed super-physiologic doses of glucocorticoids to reduce/maintain androstenedione in combination with upstream CRF1 inhibition mediated by crinecerfont?

Richard Auchus, MD, PhD

What did the investigators of the CAHtalyst pediatric trial observe in the way of weight loss in children and adolescents? Was this a pre-specified secondary end point?

What did the investigators of the CAHtalyst pediatric trial observe in the way of weight loss in children and adolescents? Was this a pre-specified secondary end point?

Richard Auchus, MD, PhD

How well was crinecerfont tolerated in the CAHtalyst pediatric trial and what was the side effect profile?

Richard Auchus, MD, PhD

What do you think are the most important clinical implications and learnings from the adult and pediatric CAHtalyst trials?

What do you think are the most important clinical implications and learnings from the adult and pediatric CAHtalyst trials?

Richard Auchus, MD, PhD

Can you discuss the specifics of the adult CAHtalyst trial evaluating crinecerfont; and in what ways it was similar and in what ways did elements differ from the pediatric age group?

Can you discuss the specifics of the adult CAHtalyst trial evaluating crinecerfont; and in what ways it was similar and in what ways did elements differ from the pediatric age group?

Richard Auchus, MD, PhD

How would you summarize the take-home lessons and translational implications of the CAHtalyst trials evaluating crinecerfont for CAH in adults and children?

How would you summarize the take-home lessons and translational implications of the CAHtalyst trials evaluating crinecerfont for CAH in adults and children?

Richard Auchus, MD, PhD